药物共付代金券对心肌梗死后P2Y12抑制剂使用及主要不良心血管事件的影响:ARTEMIS随机临床试验
结果显示代金券组患者报告的持续用药率提高(87.0% vs 83.8%,校正差值2.3%),但1年MACE无显著差异(10.2% vs 10.6%,校正差值0.66%)。
要点
- 共付代金券使心梗后1年P2Y12抑制剂持续用药率绝对提高2.3%。
- 代金券未能显著降低1年主要不良心血管事件风险。
- 高效力P2Y12抑制剂使用率在干预组低于常规 care 组。
核心结论
- 提供代金券抵消P2Y12抑制剂共付费用使患者报告的持续用药率绝对增加3.3%,但未显著减少1年MACE。
研究设计与样本
- 干预组131家医院(6436例)提供氯吡格雷或替格瑞洛1年共付代金券,常规 care 组156家医院(4565例)不提供研究代金券。
主要发现
- 1年患者报告的P2Y12抑制剂持续用药率干预组87.0%(5340/6135)高于对照组83.8%(3324/3967),P<.001,校正差值2.3%(95%CI 0.4%至4.1%),校正OR 1.19(95%CI 1.02至1.40)。
- 1年MACE累积发生率干预组10.2%与对照组10.6%无显著差异,P=.65,校正差值0.66%(95%CI -0.73%至2.06%),校正HR 1.07(95%CI 0.93至1.25)。
- 干预组6135例中4393例(72%)使用了代金券,30天供应量代金券中位价值137美元(25th-75th百分位20-339美元)。
关键数值与推荐
- 持续用药定义为无≥30天用药间隙的连续治疗。
- MACE定义为死亡、再发心肌梗死或卒中。
临床怎么用
- 消除共付费用障碍可适度改善心梗后P2Y12抑制剂持续用药,但未转化为1年MACE减少。
- 临床决策仍需综合评估患者经济障碍与获益,不能仅依赖费用补贴降低心血管事件。
局限性
- 持续用药为患者报告结局,可能存在报告偏倚。
- 干预组氯吡格雷处方比例(36.0%)低于常规 care 组(54.7%),可能影响结果解释。
- 代金券实际使用率为72%,未使用者的影响未单独分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite guideline recommendations, many patients discontinue P2Y12 inhibitor therapy earlier than the recommended 1 year after myocardial infarction (MI), and higher-potency P2Y12 inhibitors are underutilized. Cost is frequently cited as an explanation for both of these observations. OBJECTIVE: To determine whether removing co-payment barriers increases P2Y12 inhibitor persistence and lowers risk of major adverse cardiovascular events (MACE). DESIGN, SETTING, AND PARTICIPANTS: Cluster randomized clinical trial among 301 hospitals enrolling adult patients with acute MI (June 5, 2015, through September 30, 2016); patients were followed up for 1 year after discharge (final date of follow-up was October 23, 2017), with blinded adjudication of MACE; choice of P2Y12 inhibitor was per clinician discretion. INTERVENTIONS: Hospitals randomized to the intervention (n = 131 [6436 patients]) provided patients with co-payment vouchers for clopidogrel or ticagrelor for 1 year (median voucher value for a 30-day supply, $137 [25th-75th percentile, $20-$339]). Hospitals randomized to usual care (n = 156 [4565 patients]) did not provide study vouchers. MAIN OUTCOMES AND MEASURES: Independent coprimary outcomes were patient-reported persistence with P2Y12 inhibitor (defined as continued treatment without gap in use ≥30 days) and MACE (death, recurrent MI, or stroke) at 1 year among patients discharged with a prescription for clopidogrel or ticagrelor. RESULTS: Among 11 001 enrolled patients (median age, 62 years; 3459 [31%] women), 10 102 patients were discharged with prescriptions for clopidogrel or ticagrelor (clopidogrel prescribed to 2317 [36.0%] in the intervention group and 2497 [54.7%] in the usual care group), 4393 of 6135 patients (72%) in the intervention group used the voucher, and follow-up data at 1 year were available for 10 802 patients (98.2%). Patient-reported persistence with P2Y12 inhibitors at 1 year was higher in the intervention group than in the control group (unadjusted rates, 5340/6135 [87.0%] vs 3324/3967 [83.8%], respectively; P < .001; adjusted difference, 2.3% [95% CI, 0.4% to 4.1%]; adjusted odds ratio, 1.19 [95% CI, 1.02 to 1.40]). There was no significant difference in MACE at 1 year between intervention and usual care groups (unadjusted cumulative incidence, 10.2% vs 10.6%; P = .65; adjusted difference, 0.66% [95% CI, -0.73% to 2.06%]; adjusted hazard ratio, 1.07 [95% CI, 0.93 to 1.25]). CONCLUSIONS AND RELEVANCE: Among patients with MI, provision of vouchers to offset medication co-payments for P2Y12 inhibitors, compared with no vouchers, resulted in a 3.3% absolute increase in patient-reported persistence with P2Y12 inhibitors and no significant reduction in 1-year MACE outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02406677.
引用
- Wang TY, Kaltenbach LA, Cannon CP, et al. Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial. JAMA. 2019. PMID: 30620370. doi:10.1001/jama.2018.19791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。